Moderna accelerates drug discovery and workforce transformation with AI-driven data ecosystem

Moderna, a global biotech leader, has pioneered the use of AI across its R&D, manufacturing, and commercialization, fueling its rapid response to COVID-19 and driving breakthroughs in mRNA medicine discovery. The company's CIO, Brad Miller, describes an organizational vision centered on data and AI, treating mRNA as the 'software of life.' By building a proprietary data ecosystem and integrating AI algorithms throughout every business process, Moderna enables personalized drug design, rapid therapy development, and optimized manufacturing. To ensure company-wide adoption, Moderna launched the Moderna AI Academy, democratizing AI upskilling at all levels. Today, Moderna claims its 5,000-employee workforce operates at the capacity of 50,000 through AI-powered digital transformation. AI is leveraged in everything from autonomous design of personalized therapies to supply chain optimization, supporting Moderna's ambitious goals to bring 15 new products to market within five years. This cultural and technological shift aims to maximize patient impact and efficiency using Microsoft's data and AI platforms. The company's experience highlights how end-to-end AI integration can redefine timelines, productivity, and innovation in life sciences. Moderna's journey illustrates benefits for both workforce upskilling and direct business value—faster development, enhanced precision, and new medicine modalities.